Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

P&G's Lafley joins private equity firm: Clayton, Dubilier & Rice welcomes former Procter & Gamble CEO A.G. Lafley as a special partner, the firm said April 7. Lafley held various positions with P&G for 32 years, including CEO for nine years, before retiring in 2009. "His experience building strong business operations, promoting innovation, and spurring growth across global markets enhances our value-creation capabilities," said CD&R President and CEO Donald J. Gogel. Lafley said he was attracted to CD&R because of its "successful history of building long-term value by improving the operational performance of its portfolio businesses exemplifies the positive role that private equity can play in the economy." Among the firm's diverse investments are companies in fields matching Lafley's industry-specific experience, such as Sally Beauty Holdings

You may also be interested in...



Novartis CEO Jimenez Highlights OTC Switches, Consumer Acquisitions

Incoming Novartis CEO Joe Jimenez plans to expand the Swiss firm's consumer health division over the next few years after he takes the reins from his predecessor Daniel Vasella

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel